Medical Industry Feature-logo

Medical Industry Feature

ReachMD

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Location:

United States

Networks:

ReachMD

Description:

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Language:

English


Episodes

Maximizing Flu Protection: The Clinical Value of Cell-Based Vaccines

2/6/2024
Host: Jennifer Caudle, DO Guest: Victoria A. Statler, MD, MSc Test-confirmed influenza outcomes provide a specific measure of influenza vaccine effectiveness (VE) and has helped to illustrate the potential benefit of cell-based versus egg-based vaccines.1 So what data support improved VE from cell-based flu vaccines versus egg-based vaccines? To learn more, join Dr. Jennifer Caudle as she speaks with Dr. Victoria A. Statler, Associate Professor of Pediatrics at the University of Louisville and the Director of the Pediatric Transplant and Immunocompromised Host service at Norton Children’s Hospital. Reference: Stein AN, Mills C, McGovern, et al. Superior effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza over three consecutive seasons in the United States. Paper presented at: The Ninth European Scientific Working Group Influenza (ESWI) Influenza Conference; September 17-20, 2023: Valencia, Spain. USA-QIVc-23-0119 01/24

Duration:00:13:29

Unraveling the Role of Adjuvanted Flu Vaccines for Older High-Risk Patients

2/6/2024
Guest: Stephen I. Pelton, MD Influenza disproportionately affects adults 65 and older as a result of increased frequency of comorbidities and immunosenescence.1,2 And it’s also linked to neurologic, cardiovascular, and respiratory complications in high-risk groups, while potentially exacerbating underlying chronic medical conditions.1,2 So how can adjuvanted vaccines help patients who are affected? Dive in to learn more with Dr. Stephen Pelton, Professor of Pediatrics at Boston University Chobanian and Avedisian School of Medicine. References: Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15; Boston, MA. Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Vaccines. 2023; 11(10):1525. https://doi.org/10.3390/vaccines11101525 USA-FLUD-23-0011 12/23

Duration:00:09:29

Adjuvanted Vaccines: The Modern Era in Flu Prevention for Older Adults

1/24/2024
Guess what? The CDC's Advisory Committee on Immunization Practices had a unanimous vote in favor of a preferential recommendation of vaccines for the cool adults who are 65 and older—one of these options is adjuvanted influenza vaccines.1 Talk about a milestone in the world of public health! Now the burning question is why on earth did they decide on adjuvant vaccines? Let's unravel this immunization mystery together, shall we? Reference: Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 influenza season. MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. doi: 10.15585/mmwr.rr7101a1 USA-CRP-23-0037 12/23

Duration:00:03:29

Vax Myths Unveiled: Navigating Flu Vaccine Misconceptions

1/23/2024
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Wendy Wright, DNP Guest: Elias Chahine, PharmD, FCCP, FASCP While the flu may seem benign to some, it may result in up to 710,000 hospitalizations and up to 52,000 deaths every year.1 So how are current and concerning trends in declining flu vaccinations being addressed? To hear the latest updates and recommendations, join Dr. Charles Turck as he speaks with Dr. Wendy Wright, Owner and Family Nurse Practitioner at Wright & Associates Family Healthcare in New Hampshire, and Dr. Elias Chahine, Professor of Pharmacy Practice at Palm Beach Atlantic University in West Palm Beach, Florida and Clinical Pharmacy Specialist at Wellington Regional Medical Center. Reference: Disease Burden of Influenza. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/about/burden/index.html. Updated October 4, 2022. Accessed November 28, 2023. USA-CRP-23-0043 01/24

Duration:00:11:59

Engaging Neuroplasticity in Depression with Cognitive-Emotional Training

1/23/2024
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Brian Iacoviello, MD Since the thinking part of depression may involve getting stuck on the sad or the negative thoughts, there is a need to focus on not just cognitive control for information but for emotional information processing.1 And that fits with the picture that we get from brain imaging research that shows hyperactivity in the emotion-processing region of the brain and a quieting-down of the cognitive control region of the brain when people are depressed.1 To take a deep dive, join Dr. Brian Iacoviello, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City. Reference Iacoviello BM, Wu G, Alvarez E, et al. Cognitive-emotional training as an intervention for major depressive disorder. Depress Anxiety. 2014;31(8):699-706. January 2024 US.UNB.X.23.00076

Duration:00:10:59

The Importance of Pursuing Novel Treatments for Major Depressive Disorder

1/19/2024
Guest: Aderonke Pederson, MD Major depressive disorder is a mental health condition that affects millions of Americans,1 and for the past several decades, treatment has consisted mainly of antidepressant therapy and psychotherapy.2,3 However, many patients still don't achieve their treatment goals and there are many potential barriers to accessing treatment. Learn more about these unmet needs in major depressive disorder care that underscore the importance of finding new treatment approaches with Dr. Aderonke Pederson, Assistant Professor of Psychiatry at Harvard Medical School. References: National Institute of Mental Health. Major depression. National Institute of Mental Health. July 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/statistics/major-depression National Institute of Mental Health. Depression. National Institute of Mental Health. September 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/topics/depression American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. American Psychiatric Association Publishing. 2010. Accessed November 10, 2023. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf January 2024 US.UNB.X.23.00150

Duration:00:03:30

Exploring the Use of Peptide-Based Formulas in Enteral Nutrition Therapy

1/12/2024
Host: Jennifer Caudle, DO Guest: Manpreet Mundi, MD Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there’s an urgency to manage patients symptoms, and one option that’s been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr. Manpreet Mundi, Professor of Medicine in the Department of Endocrinology at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Duration:00:11:59

The Complement System in the Pathogenesis of IgA Nephropathy

1/3/2024
Guest: Richard Lafayette, MD, FACP Insights into the complement system are critical to our understanding of the pathogenesis of immunoglobin A (IgA) nephropathy.1 That’s why Dr. Richard Lafayette is here to share what we currently know about the complement system and its role in IgA nephropathy. Dr. Lafayette is a nephrologist at Stanford University Medical Center in California. References: Medjeral-Thomas NR, O'Shaughnessy MM. Adv Chronic Kidney Dis. 2020 Mar;27(2):111-119. doi: 10.1053/j.ackd.2019.12.004 319698 12/23

Duration:00:04:59

The Four-Hit Model of IgA Nephropathy Pathogenesis

1/3/2024
Guest: Jai Radhakrishnan, MD The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York. References: Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501 Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000 Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092 319698 12/23

Duration:00:05:00

A Review of Kidney Biopsy in Complement-Mediated Kidney Diseases

1/3/2024
Guest: Mark Haas, MD Kidney biopsy is the gold standard for the diagnosis of immunoglobin A (IgA) nephropathy and complement 3 glomerulopathy (C3G),1,2 and the accurate interpretation of kidney biopsy findings is important not only for diagnosis but also guiding clinical management of these conditions. Learn more about what the diagnostic process and findings for IgA nephropathy and C3G look like with Dr Mark Haas, a renal pathologist at Cedars-Sinai Medical Center in Los Angeles. References: Mehdi A, Taliercio JJ. Cleve Clin J Med. 2023;90(6)(suppl 1):e1-e4. doi:10.3949/ccjm.90.e-s1.02 Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Nephron. 2020;144(6):272-280. doi:10.1159/000507254 319698 12/23

Duration:00:06:59

Implementing LDL-C—Lowering Therapy: Conversations with the Care Team

12/19/2023
Guest: Michael Farbaniec, MD Guest: Emma Hegwood, DO Guest: Britt Heller, MSN, RN Explore the acquisition pathways and learn key strategies for implementing LEQVIO® (inclisiran) into your practice with Dr Michael Farbaniec, Lipid Clinic Director in Pennsylvania, Dr Emma Hegwood, a cardiology fellow with Dr Farbaniec in the Clinical World of Cardiology and also a LEQVIO patient, and Care Coordinator and Registered Nurse Brittany Heller. Dr Farbaniec, Dr Hegwood, and Ms Heller have all been compensated for their time.

Duration:00:08:31

A Treatment Option for Heavy Menstrual Bleeding Due to Uterine Fibroids or Moderate to Severe Pain Due to Endometriosis in Premenopausal Women

12/6/2023
Host: Jennifer Caudle, DO Guest: Rosanne Kho, MD To learn how Myfembree® (relugolix, estradiol, norethindrone acetate) could help address uterine fibroid-associated heavy menstrual bleeding or moderate to severe endometriosis pain in premenopausal women; listen to Dr. Jennifer Caudle and Dr. Rosanne Kho, Chair of the OB/GYN Department at the University of Arizona College of Medicine in Phoenix. Please scroll for Important Safety Information. Please see full Prescribing Information including BOXED WARNING here.

Duration:00:37:58

Eureka for Influenza Prevention! Cell-Based Vaccines of the Future

12/4/2023
Several factors impact vaccine effectiveness from year to year. One of them is the phenomenon of strain mismatch which may result from egg adaptation during the egg-based influenza vaccine manufacturing process.1 So what exactly is the process of egg-adaptation? Gather your esteemed colleagues from far and wide, and tune into this episode of World of Tomorrow to learn more. Reference: Rajaram S, Boikos C, Gelone DK, Gandhi A. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother. 2020;8:1-10. USA-CRP-23-0021 11/23

Duration:00:03:30

The Interconnectivity of The Cardio-Renal-Metabolic Systems and Associated Comorbidities

11/10/2023
Guest: Pamela Kushner, MD, FAAFP The Cardio-Renal-Metabolic (CRM) systems are physiologically interconnected, and each one relies on energy homeostasis tofunction properly. So why is it important for clinicians to understand the CRM continuum to identify and assess comorbidities in order to effectively treat patients with heart failure? Dive into this episode with Dr. Pam Kushner, Clinical Professor at the University of California at Irvine, a Clinical Trialist, past Chair of the American Academy of Family Physicians Drugs and Devices Committee, and a Family Medicine Doctor with a private practice in Long Beach, California. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Duration:00:06:59

Guideline Directed Medical Therapy for the Management of Heart Failure

11/10/2023
Guest: Stephen Greene, MD In 2022, the American Heart Association, American College of Cardiology, and Heart Failure Society of America created a joint guideline for the management of heart failure. Explore what the recommendations say and how they can help improve patient outcomes with Dr. Stephen Greene, an advanced heart failure specialist at Duke Heart Transplant Clinic and a cardiologist at Duke Cardiology Clinic in Durham, North Carolina. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 6/23

Duration:00:07:29

The Importance of Making an Accurate and Timely Heart Failure Diagnosis

11/10/2023
Guest: Pamela Kushner, MD, FAAFP Clinicians may agree that several challenges exist in diagnosing heart failure because patients may present with nonspecific symptoms or may have comorbidities. So what factors are important to evaluate when detecting and diagnosing heart failure in patients? Join Dr. Pam Kushner, clinical professor at the University of California at Irvine, as she walks us through the answer to this and more. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Duration:00:05:59

Heart Failure Disease State Awareness

11/10/2023
Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN There are 4 stages of heart failure, ranging from being at risk for heart failure to having an advanced condition. So what key insights should we know about the ACC/AHA stages of heart failure and the NYHA heart failure functional classifications? Discover more with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Duration:00:07:59

The Pathophysiology and Pathoetiology of Heart Failure

11/10/2023
Guest: Stephen Greene, MD One of the most important things we know about heart failure is that it doesn’t affect everyone equally, especially when you consider heart failure with reduced ejection fraction versus preserved ejection fraction. Dive into the complex pathophysiology and pathoetiology surrounding heart failure and how it differs when ejection fraction is reduced versus when it’s preserved with Dr. Stephen Greene, an advanced heart failure specialist at Duke Heart Transplant Clinic and a cardiologist at Duke Cardiology Clinic in Durham, North Carolina. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 6/23

Duration:00:05:29

The Disease Burden and Epidemiology of Heart Failure

11/10/2023
Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. SC-US-75207 3/23

Duration:00:04:29

A Treatment for NYHA Class II-III Obstructive HCM Patients

11/7/2023
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Amy Sehnert, MD With the FDA’s approval of CAMZYOS® (mavacamten), the first and only cardiac myosin inhibitor for symptomatic New York Heart Association (NYHA) class II-III adult patients, healthcare professionals and patients now have another treatment option that targets HCM at the source. Learn more about the clinical trial data that supported the FDA approval, and how healthcare professionals can prescribe CAMZYOS from Dr. Amy Sehnert, Vice President and Head of Cardiomyopathy and Heart Failure Clinical Development at Bristol Myers Squibb.

Duration:00:27:28